Phase II study of continuous 120-hour-infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent gastrointestinal adenocarcinoma.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples